Filing Flows › Companies › Entera Bio › Report card
Entera Bio earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate3 of 4 reports beat the EPS estimate
Entera Bio (ENTX) beat the analysts' EPS estimate in 3 of its last 4 reports (75%), by -1.7% on average. Next report: Nov 13, 2026, analysts expect EPS −$0.07.
Beat rate75% of 4
Average surprise-1.7%
Next reportNov 13, 2026
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS |
|---|---|---|---|---|---|
| Q to Jun 2026 | Aug 7, 2026 | −$0.08 | −$0.14 | -75.0% | $0.14 |
| Q to Mar 2026 | May 8, 2026 | −$0.08 | −$0.07 | +12.5% | $0.07 |
| Q to Dec 2025 | Mar 27, 2026 | −$0.09 | −$0.06 | +33.3% | — |
| Q to Sep 2025 | Nov 14, 2025 | −$0.09 | −$0.07 | +22.2% | $0.07 |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Entera Bio: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.